NASDAQ : SXTC
China SXT Pharmaceuticals, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · China
Last price 3.55 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 46.91K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 42,946 |
| Enterprise Value | -27.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 19, 2019 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 13,214 |
| Shares Outstanding | 13,214 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.27% |
| Owned by Institutions (%) | 84.23% |
| Float | 13,178 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.04 |
| Forward PS | n/a |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.93 |
| Quick Ratio | 7.23 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -113.13 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -27.49% |
| Return on Assets (ROA) | -15.78% |
| Return on Invested Capital (ROIC) | -284.06% |
| Return on Capital Employed (ROCE) | -23.43% |
| Weighted Average Cost of Capital (WACC) | 4.81% |
| Revenue Per Employee | $20,322 |
| Profits Per Employee | -$110,805 |
| Employee Count | 56 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.44 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -100.00% |
| 50-Day Moving Average | 175.65 |
| 200-Day Moving Average | 15,538.24 |
| Relative Strength Index (RSI) | 27.78 |
| Average Volume (20 Days) | 685,828 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 721,044 |
| Short Previous Month | 65,603 |
| Short % of Shares Out | 6.96% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.14M |
| Gross Profit | 248,702 |
| Operating Income | -7.12M |
| Pretax Income | -6.21M |
| Net Income | -6.21M |
| EBITDA | -7.05M |
| EBIT | -7.12M |
| Earnings Per Share (EPS) | n/a |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 28.32M |
| Total Debt | 1.12M |
| Net Cash | 27.20M |
| Net Cash Per Share | $2,058.41 |
| Equity (Book Value) | 29.71M |
| Book Value Per Share | n/a |
| Working Capital | 30.16M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.02M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 73,668 |
| Net Borrowing | 144,159 |
| Free Cash Flow | -4.02M |
| FCF Per Share | -$304.03 |
Margins
| Measure | Value |
|---|
| Gross Margin | 21.85% |
| Operating Margin | -625.89% |
| Pretax Margin | -545.24% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -14,448.57% |
| FCF Yield | -9,354.67% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.18 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |